Our result also showed that activation of the PERK signaling pathway, caspase 8 and 12, and NAFLD markers was significantly inhibited by treatment with IGF-I and exercise. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.